HVIVO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.8 GBX | -0.71% |
|
-0.71% | +17.05% |
| Apr. 09 | Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024 | |
| Apr. 09 | HVIVO swings to profit and commences annual dividends as outlook rosy | AN |
Presenter SpeechJustin Waite;Vox Markets Podcast;Host (Attendees)Vox Markets Podcast with Just...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.
Calendar
2024-05-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.278
GBP
Average target price
0.3607
GBP
Spread / Average Target
+29.75%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.05% | 237M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- VENN Stock
- News hVIVO plc
- Transcript : Open Orphan plc, H1 2020 Earnings Call, Sep 30, 2020